Topic: Rebif
PARIS (Reuters) - French drugmaker Sanofi said on Saturday that its experimental multiple sclerosis drug Lemtrada worked better than an older drug sold by competitor Merck KGaA at keeping patients free from relapses.New data from a late-stage trial showed that 78 percent ...
If you are looking for Rebif coupons or savings on your next prescription of Rebif for the treatment of relapsing MS , this page will provide you with information and resources on links associated with Rebif discounts and offers. There are many ...
Genzyme Corporation (Nasdaq: GENZ) today reported five-year patient data from its completed Phase 2 multiple sclerosis (MS) trial. The CAMMS223 Phase 2 trial, first reported in the New England Journal of Medicine in 2008, compared alemtuzumab to the approved MS therapy Rebif ...
Learn how one amazing woman reveresed her MS symptoms and now leads a completely normal life. Made up of the same amino acids (the major components of proteins) as the interferon beta that is naturally present in the human body, this medication ...
GENZ) today reported four-year follow-up data from its completed Phase 2 multiple sclerosis (MS) trial showing an estimated 71 percent of alemtuzumab treated patients remain free of clinically-active disease as much as three years after most patients received their last course of ...
Biogen Idec (BIIB) and Elan Corporation, plc (ELN) recently announced that they have started enrolling patients for a phase IIIb head-to-head study between Tysabri and Teva Pharmaceuticals' (TEVA) Copaxone and Merck Serono/Pfizer's (PFE) Rebif.. The randomized, rater-blinded, active-controlled study (SURPASS) will evaluate ...
On Friday, Genzyme Corp. (GENZ) presented encouraging four-year follow-up phase II data on alemtuzumab, which is being developed for the treatment of multiple sclerosis (MS). This CAMMS223 study was conducted in early, relapsing-remitting MS patients, who were randomized to receive either alemtuzumab ...
GENZ) reported today that four-year follow-up data from its completed Phase 2 multiple sclerosis (MS) trial continued to show durable reductions in relapse rate and sustained accumulation of disability three years after the majority of patients received their last course of the ...
. Data presented at the 25th Congress of the European Committee for the Treatment and Research in Multiple Sclerosis (ECTRIMS) held in Duesseldorf, Germany, from September 9-12, 2009. "The IMPROVE study confirms the consistency of the safety profile of Rebif, while showing ...
Data from an observational phase IV study of 499 patients entitled The Swiss MS Skin Project show that multiple sclerosis (MS) patients taking AVONEX (interferon beta-1a IM) reported significantly fewer injection site reactions (ISRs) compared to patients on Betaferon? (interferon beta-1b), Copaxone? ...
